71 related articles for article (PubMed ID: 12396608)
41. Characterization of killer immunoglobulin-like receptor genetics and comprehensive genotyping by pyrosequencing in rhesus macaques.
Moreland AJ; Guethlein LA; Reeves RK; Broman KW; Johnson RP; Parham P; O'Connor DH; Bimber BN
BMC Genomics; 2011 Jun; 12():295. PubMed ID: 21645414
[TBL] [Abstract][Full Text] [Related]
42. Envelope variation as a primary determinant of lentiviral vaccine efficacy.
Craigo JK; Zhang B; Barnes S; Tagmyer TL; Cook SJ; Issel CJ; Montelaro RC
Proc Natl Acad Sci U S A; 2007 Sep; 104(38):15105-10. PubMed ID: 17846425
[TBL] [Abstract][Full Text] [Related]
43. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.
Peyerl FW; Bazick HS; Newberg MH; Barouch DH; Sodroski J; Letvin NL
J Virol; 2004 Dec; 78(24):13901-10. PubMed ID: 15564498
[TBL] [Abstract][Full Text] [Related]
44. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response.
Jones NA; Wei X; Flower DR; Wong M; Michor F; Saag MS; Hahn BH; Nowak MA; Shaw GM; Borrow P
J Exp Med; 2004 Nov; 200(10):1243-56. PubMed ID: 15545352
[TBL] [Abstract][Full Text] [Related]
45. Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope.
Peyerl FW; Barouch DH; Yeh WW; Bazick HS; Kunstman J; Kunstman KJ; Wolinsky SM; Letvin NL
J Virol; 2003 Dec; 77(23):12572-8. PubMed ID: 14610180
[TBL] [Abstract][Full Text] [Related]
46. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.
O'Connor DH; Mothe BR; Weinfurter JT; Fuenger S; Rehrauer WM; Jing P; Rudersdorf RR; Liebl ME; Krebs K; Vasquez J; Dodds E; Loffredo J; Martin S; McDermott AB; Allen TM; Wang C; Doxiadis GG; Montefiori DC; Hughes A; Burton DR; Allison DB; Wolinsky SM; Bontrop R; Picker LJ; Watkins DI
J Virol; 2003 Aug; 77(16):9029-40. PubMed ID: 12885919
[TBL] [Abstract][Full Text] [Related]
47. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview.
Girard M; Habel A; Chanel C
C R Acad Sci III; 1999 Nov; 322(11):959-66. PubMed ID: 10646090
[TBL] [Abstract][Full Text] [Related]
48. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
[TBL] [Abstract][Full Text] [Related]
49. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
50. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
Allen TM; O'Connor DH; Jing P; Dzuris JL; Mothé BR; Vogel TU; Dunphy E; Liebl ME; Emerson C; Wilson N; Kunstman KJ; Wang X; Allison DB; Hughes AL; Desrosiers RC; Altman JD; Wolinsky SM; Sette A; Watkins DI
Nature; 2000 Sep; 407(6802):386-90. PubMed ID: 11014195
[TBL] [Abstract][Full Text] [Related]
51. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
[TBL] [Abstract][Full Text] [Related]
52. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
Hanke T; Samuel RV; Blanchard TJ; Neumann VC; Allen TM; Boyson JE; Sharpe SA; Cook N; Smith GL; Watkins DI; Cranage MP; McMichael AJ
J Virol; 1999 Sep; 73(9):7524-32. PubMed ID: 10438842
[TBL] [Abstract][Full Text] [Related]
53. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies.
O'Connor DH; Allen TM; Watkins DI
DNA Cell Biol; 2002 Sep; 21(9):659-64. PubMed ID: 12396608
[TBL] [Abstract][Full Text] [Related]
54. Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection.
O'Connor D; Friedrich T; Hughes A; Allen TM; Watkins D
Immunol Rev; 2001 Oct; 183():115-26. PubMed ID: 11782252
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
